A combination therapy of anti-TGFβ and ERK inhibitors is essential for targeting the EMT/MET process in CTCs.258 In addition, eribulin, a microtubule-depolymerizing agent, has been reported to suppress EMT, which might be the mechanism for metastatic breast cancer therapy. The gene discussed is TGFB1; the disease is breast cancer.